GlobalData emphasizes increasing access to testing on National HIV Testing Day, ET HealthWorld

GlobalData emphasizes increasing access to testing on National HIV Testing Day, ET HealthWorld


New Delhi: National HIV Testing Day, observed every year on June 27, recognises and addresses existing inequalities associated with HIV infection. The day is a powerful reminder of the ongoing fight against HIV and the importance of awareness, education and support for those affected. Regular HIV testing and increasing access to tests are crucial in the fight against HIV, says GlobalData.

Testing is vital in ending the HIV epidemic, which is why it is a central theme for World AIDS Day this year. The COVID-19 pandemic initially slowed HIV testing rates as public health efforts focused on COVID-19, but recent trends show a strong rebound. Public health initiatives, increased awareness and accessible testing facilities contribute to this positive change.

An estimated 18.6 million tests were sold to hospitals in the US in 2020 during the peak of the epidemic, a number that will rise to 22.9 million tests in 2022, according to the GlobalData HIV Test SKU Tracker.

“GlobalData expects this trend to continue in 2023 and 2024. Globally, WHO is pushing to reduce the spread of HIV, which starts with reducing prevalence and highlights the importance of frequent HIV testing, especially for high-risk individuals,” says Selena Yu, senior medical analyst at GlobalData.

GlobalData's report, “Human Immunodeficiency Virus (HIV) Testing 2015-2033,” shows that the global HIV testing market value grew 1.86 percent from 2015-2023, from $1.37 billion to $1.59 billion, and is projected to exceed $2 billion by 2033. Roche has the largest market share globally at 14.6 percent, while Abbott ranks second with 11.9 percent and Siemens Healthineers is third with 9.2 percent.

Yu concluded, “The HIV testing market is continually evolving as self-testing becomes a popular option. Despite campaigns to destigmatize HIV/AIDS, at-risk individuals still feel uncomfortable getting tested. Positive test results require follow-up testing by a healthcare professional. An important player in HIV self-testing is OraQuick, a subsidiary of OraSure, as it is the only FDA-approved rapid HIV self-test currently available in the US market. Private testing options may encourage at-risk individuals to test more frequently.”

  • Published on June 27, 2024 at 12:26 PM IST

Join a community of 2M+ industry professionals

Subscribe to our newsletter to get the latest information and analysis.

Download ETHealthworld App

  • Get realtime updates
  • Save your favourite articles

icon g play

icon app store

Scan to download the app
health barcode

join us for quick updates

Leave a Reply

Your email address will not be published. Required fields are marked *

Enable Notifications OK No thanks